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gram. She had been on Hormone Replacement Therapy (HRT) for
5 years from the age of 50 to 55 for menopausal symptoms. Her Body
Mass Index (BMI) was 28.
Speculum examination revealed a 4 cm polypoid, ﬂeshy, pale tumor
based on the cervix with early involvement of the anterior vaginal
fornix. A biopsy was taken and the histopathology showed a poorly
differentiatedmalignant tumor (Fig. 1). Immunohistochemistry showed
strong positivity for S100 (Fig. 2), vimentin,melanin-A,MITF andpatchy
positivity for HM45 (Fig. 3). Epithelial and neuroendocrine markers
were negative, establishing the diagnosis of a malignant melanoma.Introduction
Malignant melanomas involving mucosal membranes, mucosal
melanomas, account for less than 0.03% of all newly diagnosed cancers
and only 2% of those are discovered in female genital tract (Patrick et al.,
2007). Primary malignant melanoma of the uterine cervix is a very rare
entity with only 81 cases reported in the literature since 1889 and their
prognosis is poor, regardless of the stage at the time of diagnosis
(Pusceddu et al., 2011).
We present the case of a FIGO stage IIa1 primary cervical melanoma
which has been successfully treated surgically and has an ongoing
survival and disease free period of 40 months. This is an exceptionally
long survival given the locally bulky disease and could be explained
by the absence of occult distant metastasis and good local control
offered by the radical surgical excision.Case report
A 63-year-old patient, para-3 presented with a four-month in-
creased vaginal foul-smelly discharge and occasional slight bleeding.
She was generally ﬁt and well, on medication for hypothyroidism,
depression and atopic dermatitis. Her maternal grandmother diedicester, Leicester, UK.
. Myriokefalitaki).
Inc. Open access under CC BY-NC-ND licensPatient underwent an extensive search for melanotic lesion of skin
or other sites, which was negative. There was no evidence of extra-
cervical disease on a CT scan of chest, abdomen and pelvis. On MRI
imaging, a lesion occupying the cervix and extending both anteriorly
(31 × 11 × 12 mm) and posteriorly (13 × 16 × 14 mm) of the exter-
nal oswas identiﬁed. Therewas possible involvement of vaginal fornices
but no evidence of parametrial involvement (Supplementary Fig. 4). Ad-
ditionally a 12 mmequivocal right external iliac lymph nodewas noted.
Patient underwent a Type III, Radical Abdominal Hysterectomy
with bilateral salpingo-oophorectomy, bilateral pelvic lymph node dis-
section and removal of the upper vagina with a cuff of 45 × 35 mm
(Supplementary Figs. 5 and 6). Final histopathological report veriﬁedFig. 1. Immunohistochemistry (IHC) images H&E at ×200 magniﬁcation.
e.
Fig. 2. Immunohistochemistry (IHC) images for S100 at ×200 magniﬁcation.
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33 × 22 × 35 mm, obscuring the external os and extending into the
endocervical canal. The tumor composed of solid sheets of malignant
epithelioid cells, in keeping with the biopsy. There was non-brisk
lymphocytic response and the mitotic count was up to 16 per 10
high-powered ﬁelds. There were no ulcerations, features of regression,
microsatellite lesions, lymphovascular or perineural space invasion.
The tumor was conﬁned within the cervix and all pelvic lymph nodes
removed were free of neoplasia. Histopathologically, this was a FIGO
stage IIa1 and Clark's Level IV. Following surgery, no adjuvant therapy
was commenced as the tumor had been resected with a 12.1 mm
clear peripheral microscopic cuff margin and 7.1 mm free parametrial
soft tissue margin. Patient has been on a regular 3 monthly clinical
follow-up with pelvic examination and skin inspection. She is disease-
free and active in her daily life, 40 months following her diagnosis.
Therewere no additional symptoms reported that needed investigating.Discussion
Mucosal Melanomas (MM) occur more frequent in older ages and
postmenopausal women. Almost 73% of cases involved women aged
over 60 years old. The incidence of genital tract mucosal melanomasFig. 3. Immunohistochemistry (IHC) images for HMB45 at ×200 magniﬁcation.has been estimated at 1.6 cases per 1 million females with only less
than 2% accoutering for cervix MM (McLaughin et al., 2005).
The etiology of cervical MM is unknown. It was only in 1959 when
basal melanocytes were identiﬁed in cervical biopsies by Cid S.J.
Melanocyte migration from neural crest or melanocytic differentiation
from the endocervical epithelium are two theories for the presence
of those melanocytes on the cervix (Zamiati et al., 2001). Risk factors
such as HPV 16, radiotherapy or estrogen hormonal inﬂuence has been
proposed as per case reports in the literature. Furthermore, hypothetic
mechanisms have been suggested, but none can be identiﬁed as speciﬁc,
hence primary cervical MM is a very rare entity and conclusions can not
be safely made (Pusceddu et al., 2011).
MM is more likely to present as vaginal discharge, dyspareunia and/
or bleeding either post coital or more frequently post menopausal.
Macroscopically, it appears as a polypoid or exophytic mass of the
cervix. Tumor size may vary and pigmentation can be generally dark,
black, blue or reddish and in occasions of amelanotic tumors, pale or
white (Deshpande and Munshi, 2001). Diagnosis is made by immuno-
staining as MMs are frequently positive for S100, vimentin, melanin A,
MART1 and HMB45. Protein S100 is considered more sensitive, and
protein HMB45 a rather more speciﬁc stain to set the diagnosis of MM
especially when the two markers are combined (Deshpande and
Munshi, 2001). The criteria for diagnosis of a primary cervical MM
include: presence ofmelanin in the normal cervical epithelium, absence
of melanoma in other body areas, evidence of junctional changes in
the cervix, and metastases according to the pattern of cervical cancer
(Pusceddu et al., 2011).
Diagnosis is made by obtaining biopsy of those suspicious, polypoid
cervical tumors at presentation with the above-mentioned symptoms,
or incidentally after speculum assessment in routine gynecological
examination. Early diagnosis in Papanicolaou smear test, colposcopy,
or liquid-based cytology has also been reported (Deshpande and
Munshi, 2001; Jin et al., 2007). This emphasizes the need of specialist
cytopathologist reviewing cervical smears and biopsies, to keep
in mind this infrequent pathology and apply the appropriate staining
in cases that melanin pigmentated cells, high grade squamous intra-
epithelial lesions or poorly differentiated cells are encountered (Jin
et al., 2007).
Although staging of primary cutaneous melanomas is based on the
thickness of the primary lesion, primary cervical MM is staged
accordingly to the FIGO system for cervical cancer; as this correlates
better with survival (Pusceddu et al., 2011).
Treatment of choice for MM is surgical with the excision of the
tumor in wide clear margins (Pusceddu et al., 2011; Piura, 2008). This
approach stands also for other MM like anorectal, which is equally
rare and better studied in the literature (Nilsson and Ragnarsson-
Olding, 2010). Although there is no consensus for a standardized surgi-
cal approach in cervical MM, radical hysterectomy sometimes coupled
with regional lymphadenectomy and/or vaginectomy are generally
performed (Mousavi et al., 2006).
MM is a known radio-resistant tumor. Therefore, radiotherapy has
been reserved for: a) palliative treatment of recurrences, b) in
advance disease, c) unsatisfactory surgical margins, d) parametrial
invasion, e) residual tumors, or f) pelvic lymph node involvement.
Treatment outcomes are variable (Mousavi et al., 2006). At present,
the same chemotherapy protocols used for skin melanoma are
applied for cases of advanced or recurrent cervical MM (Piura, 2008).
Although objective response to treatment was noticed, survival was not
signiﬁcantly improved. Immunotherapy with high dose Interleukin-2
has shown promising results in a small percentage of cases with meta-
static disease (Bhatia et al., 2009).
Cervical MM is highly aggressive as both local recurrence and
wide spread metastases usually occur within a short span of a few
months to two years from initial diagnosis (Zamiati et al., 2001).
Relapse is more likely to be local (vagina, vulva or alongside suture
line) rather than distant, stressing the value of clinical examination as
54 E. Myriokefalitaki et al. / Gynecologic Oncology Reports 5 (2013) 52–54part of routine follow-up. Regardless of stage and treatment, prognosis
of cervical MM is consequently extremely poor, as 87.5% of patients,
reported in literature, diedwithin 36 months of diagnosis (22.9 months
overall mean survival). This is despite the fact that almost 41% of cases
have been diagnosed at FIGO stage I disease. Globally, the 5-year survival
is 18.8% for stage I, 11.1% for stage II and 0% for stages III–IV (Pusceddu
et al., 2011). There is no consistency into the Cervical MM treatment
approach, probably due to its rarity, so safe conclusions can't be made.
Studies on other MM, like anorectal where larger numbers are available,
have showed that resection status and tumor stage are independent
prognostic variables and provided clear resectionmargins; there is a sig-
niﬁcantly better overall 5-year survival. (Nilsson andRagnarsson-Olding,
2010) Due to MM radio resistance, Gynae Oncologists should consider
and discuss with patient extend of surgical resection.Conclusion
Primary CervicalMMprognosis is poor and literature review suggests
that the only available primary treatment is surgical excision of the
tumor in wide clear margins. Our case reinforces this statement.
Although the size of the primary tumor, clear resectionmargins, negative
lymph node status and absence of lymphovascular space invasion, led to
a better disease free survival. We suggest that these rare tumors should
be discussed by a specialist multidisciplinary team and surgical excision
with curative intent should be the primary approach. Adjuvant chemo-
therapy and radiotherapy, with or without surgical excision to control
local symptoms, are used as palliative treatment in advance stages and
disease recurrences with variable outcomes.
It is very crucial to diagnose MM of the cervix and treat at an early
stage. Routine pelvic examination and cervical inspection should be a
part of clinical assessment especially for patients presenting with vagi-
nal bleeding or discharge.Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.gynor.2013.04.004.
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